Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA 30a Mediated Autophagy and Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Imatinib Mesylate is the drug used for targeted tyrosine kinase inhibition in the beginning of management of all Chronic Myeloid Leukemia (CML) newly diagnosed cases. However, resistance presents a considerable limit to its efficacy. Currently, it is impossible to anticipate IM resistance which makes the recognition of early flags an important treatment goal in CML. In this work we studied the connection between microRNA 30a (miR-30a) and Beclin 1 mediated autophagy and IM resistance in Egyptian CML patients. The study included newly diagnosed (group I, n = 20), imatinib responder (group II, n = 30), imatinib resistant (group III, n = 30) CML patients and a healthy demographically matched control group (group IV, n = 20). miR-30a expression was assayed by quantitative reverse transcription polymerase chain reaction. The variation in expression of miR-30a between CML cases and healthy controls was calculated using relative quantification method (2−ΔΔCT). Beclin 1 was assayed in Peripheral blood mononuclear cells by western blotting. miR-30a was over expressed and Beclin 1 was under expressed in imatinib responders compared to resistant cases median 1.21(0.55–3.02) versus median 0.65 (0.03–1.0) (p = 0.001) and median 950.0 (400.0–2410.0) versus, median 1570.0 (920.0–5430.0) (p < 0.001) respectively. Beclin 1 correlated significantly positively with miR-30a in new cases (p = 0.001) and negatively in imatinib responders (p = 0.021). Receiver Operating Curves demonstrated the performances of miR-30a and Beclin 1 to detect imatinib resistance. They showed sensitivities of 97.14% and 94.29% and specificities of 53.33% and 42.22% at the cut-off values of 1 and 940 respectively. Both miR-30a and Beclin 1 levels showed a relation with imatinib response and can therefore be put forward as valuable markers for detection of resistance and may also have promising future therapeutic implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Faderl STM, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172

    Article  CAS  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30

    Article  PubMed  Google Scholar 

  3. Nowell PC (2007) Discovery of the Philadelphia chromosome: a personal perspective. J Clin Investig 117(8):2033–2035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. DeAngelo DJ, Ritz J (2004) Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer? Clin Cancer Res 10(1):1–3

    Article  CAS  PubMed  Google Scholar 

  5. Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8(11):1018–1029

    Article  CAS  PubMed  Google Scholar 

  6. Shintani T, Klionsky DJ (2004) Autophagy in health and disease: a double-edged sword. Science 306(5698):990–995

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hamilton A (2010) Investigation into the relevance of BCR-ABL for the survival of cancer stem cells in chronic myeloid leukaemia. University of Glasgow

  8. Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P et al (2012) Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 26(8):1752

    Article  CAS  PubMed  Google Scholar 

  9. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R et al (2018) Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16(9):1108–1135

    Article  Google Scholar 

  10. Beillard E, Pallisgaard N, Van der Velden V, Bi W, Dee R, van der Schoot E et al (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia 17(12):2474

    Article  CAS  PubMed  Google Scholar 

  11. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 − ΔΔCT method. Methods 25(4):402–408

    Article  CAS  PubMed  Google Scholar 

  12. Waterborg JH (2009) The Lowry method for protein quantitation. Springer, The protein protocols handbook, pp 7–10

    Google Scholar 

  13. Gozuacik D, Akkoc Y, Ozturk DG, Kocak M (2017) Autophagy-regulating microRNAs and cancer. Front Oncol 7:65

    Article  PubMed  PubMed Central  Google Scholar 

  14. San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L et al (2009) MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer 8(1):69

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yang X, Chen Y, Chen L (2017) The versatile role of microRNA-30a in human cancer. Cell Physiol Biochem 41(4):1616–1632

    Article  CAS  PubMed  Google Scholar 

  16. Zou Z, Wu L, Ding H, Wang Y, Zhang Y, Chen X et al (2012) MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 287(6):4148–4156

    Article  CAS  PubMed  Google Scholar 

  17. Carew JS, Nawrocki ST, Giles FJ, Cleveland JL (2008) Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biol Targets Therapy 2(2):201

    CAS  Google Scholar 

Download references

Funding

No funding was received by the authors for conducting this study.

Author information

Authors and Affiliations

  1. Medical Biochemistry Department, Mowasah Medical Campus, Alexandria Faculty of Medicine, Main University Hospital, Alexandria, Egypt

    Nehal A. Khalil, Mohammed N. Desouky, Iman H. Diab & Hazem F. Mannaa

  2. Hematology Department, Alexandria Faculty of Medicine, Alexandria, Egypt

    Nahla A. M. Hamed

Authors
  1. Nehal A. Khalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed N. Desouky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iman H. Diab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nahla A. M. Hamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hazem F. Mannaa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nehal A. Khalil.

Ethics declarations

Conflict of interest

The authors declare they have potential conflicts of interest, neither financial nor non-financial.

Human and Animal Rights

The study was conducted using human blood samples and an approval by the Ethics Review Board of the Alexandria University, Faculty of Medicine was obtained.

Informed Consent

Subjects’ informed consent was obtained upon sample withdrawal.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khalil, N.A., Desouky, M.N., Diab, I.H. et al. MicroRNA 30a Mediated Autophagy and Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients. Indian J Hematol Blood Transfus 36, 491–497 (2020). https://doi.org/10.1007/s12288-019-01241-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01241-3

Keywords

Search

Navigation